B. Riley Securities Maintains Buy on CymaBay Therapeutics, Raises Price Target to $16
Portfolio Pulse from richadhand@benzinga.com
B. Riley Securities analyst Mayank Mamtani maintains a Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and has raised the price target from $8 to $16.
July 31, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CymaBay Therapeutics' price target has been raised from $8 to $16 by B. Riley Securities, which maintains a Buy rating on the stock.
The doubling of the price target by B. Riley Securities indicates a strong positive outlook for CymaBay Therapeutics. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100